Arcutis Biotherapeutics Inc [ARQT] stock prices are down -0.89% to $14.51 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ARQT shares have gain 4.99% over the last week, with a monthly amount glided 7.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $19. Previously, Jefferies started tracking the stock with Buy rating on August 28, 2024, and set its price target to $15. On January 03, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $8 on the stock. Mizuho downgraded its rating to a Neutral and decreased its price target to $4 on October 26, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $6 on October 13, 2023. Needham started tracking with a Buy rating for this stock on September 07, 2022, and assigned it a price target of $46. In a note dated March 17, 2022, Goldman initiated an Buy rating and provided a target price of $45 on this stock.
The stock price of Arcutis Biotherapeutics Inc [ARQT] has been fluctuating between $6.99 and $17.75 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $14.51 at the most recent close of the market. An investor can expect a potential return of 30.94% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
The Arcutis Biotherapeutics Inc [NASDAQ:ARQT] reported sales of 212.82M for trailing twelve months, representing a surge of 32.84%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -0.57%, Pretax Profit Margin comes in at -0.61%, and Net Profit Margin reading is -0.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.81 and Total Capital is -0.48. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.78.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Arcutis Biotherapeutics Inc [NASDAQ:ARQT]’s Current Ratio is 3.55. On the other hand, the Quick Ratio is 3.37, and the Cash Ratio is 0.58. Considering the valuation of this stock, the price to sales ratio is 8.13, the price to book ratio is 12.12.
Transactions by insiders
Recent insider trading involved Edwards Larry Todd, that happened on May 19 ’25 when 7451.0 shares were sold. Director, Heron Patrick J completed a deal on May 15 ’25 to buy 2520.0 shares. Meanwhile, Officer Edwards Larry Todd bought 7451.0 shares on May 19 ’25.
